NeoGenomics Secures Medicare Coverage for PanTracer LBx Test
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 16 2026
0mins
Should l Buy NEO?
Source: Newsfilter
- Medicare Coverage Milestone: NeoGenomics' PanTracer LBx test has received coverage from Medicare, significantly enhancing accessibility to precision oncology in community settings, which is expected to lead to more patients receiving personalized treatment.
- Blood Test Advantages: The test provides actionable biomarker information from a simple blood draw, evaluating over 500 genes with a seven-day turnaround, meeting the flexible needs of both patients and clinicians, thereby promoting the adoption of advanced cancer diagnostics.
- Clinical Application Expansion: PanTracer LBx complements the PanTracer Tissue test, enabling comprehensive tumor profiling and reducing barriers for patients to access advanced cancer diagnostics, further solidifying NeoGenomics' market position in precision oncology.
- Market Potential: The Medicare coverage decision is anticipated to drive clinical adoption of PanTracer LBx, enhancing physicians' ability to deliver timely, personalized treatment strategies, thereby increasing the real-world utility of patient care.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NEO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NEO
Wall Street analysts forecast NEO stock price to rise
11 Analyst Rating
5 Buy
6 Hold
0 Sell
Moderate Buy
Current: 7.200
Low
12.00
Averages
14.00
High
16.00
Current: 7.200
Low
12.00
Averages
14.00
High
16.00
About NEO
NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
U.S. Launches $12 Billion Strategic Minerals Reserve Initiative
- Project Launch: On February 2, 2026, the White House initiated Project Vault, a $12 billion strategic minerals reserve program aimed at covering all 60 minerals on the USGS Critical Minerals List, highlighting the government's commitment to securing mineral supply chains.
- International Cooperation: During the 2026 Critical Minerals Ministerial, Secretary of State Rubio confirmed over $30 billion in U.S. government support for secure supply chains, reflecting America's strategic positioning in the global mineral resource competition.
- Market Dynamics: The IEA projects a 30% copper shortfall by 2035, while rare earth supplies outside China meet less than 40% of projected demand, creating upward pressure on commodity prices, particularly as uranium approaches $92 per pound amid rising reactor demand.
- Corporate Positioning: EagleOne Metals recently acquired the Poison Springs uranium/rare earth project in Utah for $50,000, showcasing its diversified exposure in critical minerals, which is expected to enhance its market value and competitive edge.
See More
NeoGenomics Secures Medicare Coverage for PanTracer LBx Test
- Medicare Coverage Milestone: NeoGenomics' PanTracer LBx test has received coverage from Medicare, significantly enhancing accessibility to precision oncology in community settings, which is expected to lead to more patients receiving personalized treatment.
- Blood Test Advantages: The test provides actionable biomarker information from a simple blood draw, evaluating over 500 genes with a seven-day turnaround, meeting the flexible needs of both patients and clinicians, thereby promoting the adoption of advanced cancer diagnostics.
- Clinical Application Expansion: PanTracer LBx complements the PanTracer Tissue test, enabling comprehensive tumor profiling and reducing barriers for patients to access advanced cancer diagnostics, further solidifying NeoGenomics' market position in precision oncology.
- Market Potential: The Medicare coverage decision is anticipated to drive clinical adoption of PanTracer LBx, enhancing physicians' ability to deliver timely, personalized treatment strategies, thereby increasing the real-world utility of patient care.
See More
NeoGenomics Launches RaDaR ST for Molecular Residual Disease Detection
- Significant Market Potential: The MRD market is estimated to exceed $20 billion, growing at an annual rate of 30%, with less than 10% penetration, presenting substantial growth opportunities for NeoGenomics' RaDaR ST and potentially driving future revenue growth.
- Technological Innovation: RaDaR ST detects trace amounts of tumor DNA in blood using patient-specific tumor-informed panels, achieving a sensitivity of 95%, enabling early detection before recurrence is visible on imaging, thus aiding clinicians in making more informed treatment decisions.
- Broad Clinical Applications: The assay has been validated in various cancers, including breast and HPV-negative head and neck cancers, demonstrating effectiveness for long-term surveillance and early recurrence detection in high-risk populations, further solidifying NeoGenomics' leadership in oncology diagnostics.
- Comprehensive Solution: The launch of RaDaR ST allows NeoGenomics to offer a complete solid tumor care solution, enhancing the company's competitiveness across the entire cancer treatment continuum from comprehensive diagnostics to personalized MRD assessment.
See More
NeoGenomics Reports Record Q4 2025 Revenues of $190 Million
- Significant Revenue Growth: NeoGenomics reported Q4 2025 revenues of $190 million, an 11% year-over-year increase, with clinical business revenue rising 16%, demonstrating the company's strong market performance and effective execution of its commercial strategy.
- Strong NGS Performance: The company achieved a 23% growth in NGS revenue, significantly outpacing the market growth rate, indicating its leadership position and increased market share in high-value testing.
- Synergies from Pathline Acquisition: The acquisition of Pathline is expected to yield operational efficiencies and synergies, with profitability improvements anticipated to begin in 2026, further strengthening the company's lab network.
- Optimistic 2026 Outlook: NeoGenomics projects 2026 revenues between $793 million and $801 million, with adjusted EBITDA expected to grow by 27% to 31%, reflecting confidence in future growth driven by the launches of RaDaR ST and PanTracer products, which are expected to accelerate revenue growth.
See More
NeoGenomics Q4 Earnings Exceed Expectations
- Strong Earnings Performance: NeoGenomics reported a Q4 non-GAAP EPS of $0.06, beating expectations by $0.02, indicating ongoing improvements in profitability and boosting investor confidence.
- Significant Revenue Growth: The company achieved Q4 revenue of $190.17 million, an 11% year-over-year increase, surpassing market expectations by $1.89 million, demonstrating its strengthening competitive position in the market.
- Increased Testing Revenue: Average revenue per clinical test rose by 5% to $488, with a 7% increase excluding recently acquired Pathline tests, reflecting a strategic shift towards higher-value tests and the positive impact of reimbursement initiatives.
- 2026 Financial Guidance: The company issued its 2026 financial guidance, projecting revenue between $793 million and $801 million, representing a 9% to 10% year-over-year increase, while also forecasting a reduction in net loss to $63 million, indicating potential improvements in future profitability.
See More
NeoGenomics to Announce Q4 Earnings on February 17
- Earnings Announcement Date: NeoGenomics is set to release its Q4 earnings on February 17 before market open, with a consensus EPS estimate of $0.04, indicating stable profitability year-over-year.
- Revenue Growth Expectations: The anticipated revenue for Q4 is approximately $190 million, reflecting a 9.4% year-over-year increase, which highlights the ongoing demand and market expansion capabilities in community oncology.
- Historical Performance Review: Over the past two years, NeoGenomics has beaten EPS estimates 100% of the time and revenue estimates 63% of the time, demonstrating reliability in financial forecasting.
- Estimate Revision Dynamics: In the last three months, EPS estimates saw no upward revisions and two downward adjustments, while revenue estimates experienced one upward revision and two downward adjustments, indicating a cautious market outlook on the company's future performance.
See More
U.S. Launches $12 Billion Strategic Minerals Reserve Initiative
- Project Launch: On February 2, 2026, the White House initiated Project Vault, a $12 billion strategic minerals reserve program aimed at covering all 60 minerals on the USGS Critical Minerals List, highlighting the government's commitment to securing mineral supply chains.
- International Cooperation: During the 2026 Critical Minerals Ministerial, Secretary of State Rubio confirmed over $30 billion in U.S. government support for secure supply chains, reflecting America's strategic positioning in the global mineral resource competition.
- Market Dynamics: The IEA projects a 30% copper shortfall by 2035, while rare earth supplies outside China meet less than 40% of projected demand, creating upward pressure on commodity prices, particularly as uranium approaches $92 per pound amid rising reactor demand.
- Corporate Positioning: EagleOne Metals recently acquired the Poison Springs uranium/rare earth project in Utah for $50,000, showcasing its diversified exposure in critical minerals, which is expected to enhance its market value and competitive edge.
See More
NeoGenomics Secures Medicare Coverage for PanTracer LBx Test
- Medicare Coverage Milestone: NeoGenomics' PanTracer LBx test has received coverage from Medicare, significantly enhancing accessibility to precision oncology in community settings, which is expected to lead to more patients receiving personalized treatment.
- Blood Test Advantages: The test provides actionable biomarker information from a simple blood draw, evaluating over 500 genes with a seven-day turnaround, meeting the flexible needs of both patients and clinicians, thereby promoting the adoption of advanced cancer diagnostics.
- Clinical Application Expansion: PanTracer LBx complements the PanTracer Tissue test, enabling comprehensive tumor profiling and reducing barriers for patients to access advanced cancer diagnostics, further solidifying NeoGenomics' market position in precision oncology.
- Market Potential: The Medicare coverage decision is anticipated to drive clinical adoption of PanTracer LBx, enhancing physicians' ability to deliver timely, personalized treatment strategies, thereby increasing the real-world utility of patient care.
See More
NeoGenomics Launches RaDaR ST for Molecular Residual Disease Detection
- Significant Market Potential: The MRD market is estimated to exceed $20 billion, growing at an annual rate of 30%, with less than 10% penetration, presenting substantial growth opportunities for NeoGenomics' RaDaR ST and potentially driving future revenue growth.
- Technological Innovation: RaDaR ST detects trace amounts of tumor DNA in blood using patient-specific tumor-informed panels, achieving a sensitivity of 95%, enabling early detection before recurrence is visible on imaging, thus aiding clinicians in making more informed treatment decisions.
- Broad Clinical Applications: The assay has been validated in various cancers, including breast and HPV-negative head and neck cancers, demonstrating effectiveness for long-term surveillance and early recurrence detection in high-risk populations, further solidifying NeoGenomics' leadership in oncology diagnostics.
- Comprehensive Solution: The launch of RaDaR ST allows NeoGenomics to offer a complete solid tumor care solution, enhancing the company's competitiveness across the entire cancer treatment continuum from comprehensive diagnostics to personalized MRD assessment.
See More
NeoGenomics Reports Record Q4 2025 Revenues of $190 Million
- Significant Revenue Growth: NeoGenomics reported Q4 2025 revenues of $190 million, an 11% year-over-year increase, with clinical business revenue rising 16%, demonstrating the company's strong market performance and effective execution of its commercial strategy.
- Strong NGS Performance: The company achieved a 23% growth in NGS revenue, significantly outpacing the market growth rate, indicating its leadership position and increased market share in high-value testing.
- Synergies from Pathline Acquisition: The acquisition of Pathline is expected to yield operational efficiencies and synergies, with profitability improvements anticipated to begin in 2026, further strengthening the company's lab network.
- Optimistic 2026 Outlook: NeoGenomics projects 2026 revenues between $793 million and $801 million, with adjusted EBITDA expected to grow by 27% to 31%, reflecting confidence in future growth driven by the launches of RaDaR ST and PanTracer products, which are expected to accelerate revenue growth.
See More
NeoGenomics Q4 Earnings Exceed Expectations
- Strong Earnings Performance: NeoGenomics reported a Q4 non-GAAP EPS of $0.06, beating expectations by $0.02, indicating ongoing improvements in profitability and boosting investor confidence.
- Significant Revenue Growth: The company achieved Q4 revenue of $190.17 million, an 11% year-over-year increase, surpassing market expectations by $1.89 million, demonstrating its strengthening competitive position in the market.
- Increased Testing Revenue: Average revenue per clinical test rose by 5% to $488, with a 7% increase excluding recently acquired Pathline tests, reflecting a strategic shift towards higher-value tests and the positive impact of reimbursement initiatives.
- 2026 Financial Guidance: The company issued its 2026 financial guidance, projecting revenue between $793 million and $801 million, representing a 9% to 10% year-over-year increase, while also forecasting a reduction in net loss to $63 million, indicating potential improvements in future profitability.
See More
NeoGenomics to Announce Q4 Earnings on February 17
- Earnings Announcement Date: NeoGenomics is set to release its Q4 earnings on February 17 before market open, with a consensus EPS estimate of $0.04, indicating stable profitability year-over-year.
- Revenue Growth Expectations: The anticipated revenue for Q4 is approximately $190 million, reflecting a 9.4% year-over-year increase, which highlights the ongoing demand and market expansion capabilities in community oncology.
- Historical Performance Review: Over the past two years, NeoGenomics has beaten EPS estimates 100% of the time and revenue estimates 63% of the time, demonstrating reliability in financial forecasting.
- Estimate Revision Dynamics: In the last three months, EPS estimates saw no upward revisions and two downward adjustments, while revenue estimates experienced one upward revision and two downward adjustments, indicating a cautious market outlook on the company's future performance.
See More
